Abstract
Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). We assessed the clinical presentation and treatment outcomes of ICI-mediated psoriasiform eruptions in our center. In this retrospective study we queried data registries of Dana-Farber Cancer Institute/Mass General Brigham through February 2020. Patients with de novo ICI-induced psoriasis or flared up psoriasis post-ICI were included. Known psoriasis who did not flare up were excluded.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
